According to Tekmira, AlCana is an “instrument of Alnylam” used to “escape the licensing and royalty obligations” of the companies' agreements.
"Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in preclinical models," the companies said.
NPR reports that Turkish high school students will no longer study evolution.
Researchers report they sequenced and identified plant species in an "al fresco" laboratory.
An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.
In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.